Chardan Capital Markets Downgrades Ocugen, Inc. (OCGN) to Neutral Following Run-Up
- Wall Street ends mixed despite bumper big-bank earnings
- Coinbase (COIN) Soars 52% in Public Debut
- Thermo Fisher Scientific (TMO) Nears Deal to Buy PPD, Inc. (PPD) for More Than $15 Billion -DJ
- JPMorgan (JPM) Reports a Q1 Beat on Revenue and Profit Fueled by Release of $5.2 Billion Reserved for Bad Loans; Shares Slightly Down
- Dell Technologies (DELL) Announces Planned VMware (VMW) Spin-Off
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Chardan Capital Markets analyst Keay Nakae downgraded Ocugen, Inc. (NASDAQ: OCGN) from Buy to Neutral with a price target of $13.00.
The analyst commented, "The stock has increased from $0.29 to $15.81 since announcing on 22 December 2020 its intention to co-develop Bharat Biotech’s Covid-19 vaccine candidate, COVAXIN, for the U.S. market. Under the agreement, Ocugen will have U.S. rights to the vaccine candidate and will be responsible for obtaining FDA Emergency Use Authorization (EUA) for COVAXIN. What this will require is uncertain at this point, including the possibility of an additional U.S. based study, but will certainly be highly dependent on the results from the ongoing phase III study in India. Topline data from this study is expected in March 2021. Ocugen will also be responsible for establishing manufacturing of the vaccine in the U.S. and for all this will be entitled to 45% of the profits from U.S. sales."
Shares of Ocugen, Inc. closed at $13.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hong Kong Exchanges (388:HK) (HKXCY) PT Lowered to HK$570 at Citi
- United Microelectronics Corp (2303:TT) (UMC) PT Raised to TWD67 at Credit Suisse
- MediaTek Inc. (2454:TT) (MDTKF) PT Raised to NT$1,250 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades
Related EntitiesChardan Capital Markets, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!